Codexis, Inc.
HealthcareNASDAQ:CDXS · NASDAQ Global Select
-$0.01 today
Vol 0.35M · Avg 1.98M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.0%
avg -47.7%
ROIC
-30.6%
avg -31.8%
ROA
-29.8%
avg -24.4%
Analysis
ROA is currently the strongest return metric at -29.8% versus its period average of -24.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alison Moore | President, Chief Executive Officer & Director | $1.00M | — | 59 | $993,000.00 | 1.09% |
Georgia L. Erbez | Chief Financial Officer & Chief Business Officer | $745,963.00 | — | 59 | $316,100.00 | 0.35% |
Stefan Lutz | Chief Scientific Officer | $729,162.00 | — | — | $130,421.00 | 0.14% |
Senator Byron L. Dorgan | Consultant | $26,786.00 | — | 83 | $223,581.00 | 0.25% |
John Schiffhauer | Senior Vice President of Intellectual Property | — | — | — | $783,965.00 | 0.86% |
Carrie McKim | Director of Investor Relations | — | — | — | — | — |
Karen Frechou-Armijo | Senior Vice President & Head of Human Resources | — | — | — | — | — |
Britton Jimenez | Senior Vice President of Sales & Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$3.60M
Sells
24
$3.20M
Net Sentiment
+$393,177.80
Net buying
Most Active
Opaleye Management Inc.
25 transactions
1–10 of 35
Analysis
Insiders reported 11 buys worth $3.60M and 24 sells worth $3.20M over the last 12 months. That adds up to net buying of $393,177.80. Opaleye Management Inc. was the most active insider with 25 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -22.1% | +10.1% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -22.1% over three years. Forward estimates point to Revenue at +10.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Who manages CDXS?
Codexis, Inc. (CDXS) lists 8 active executives. The top listed executive is John Schiffhauer, Senior Vice President of Intellectual Property.
Are CDXS insiders buying or selling?
Recent insider activity shows net buying of $29.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.